WEBULL
News
PFE-WI
35.40
0.00%
0.00
Telescope Innovations posts FY 2025 expenses of CAD 7.3 million, up 26 percent
Reuters · 5d ago
PFIZER: PARTICIPANT IN LONG-TERM EXTENSION TRIAL STUDYING MARSTACIMAB IN PEOPLE LIVING WITH HEMOPHILIA A/B WITH/WITHOUT INHIBITORS PASSED AWAY IN DEC
Reuters · 5d ago
PFIZER: SAFETY AND WELL-BEING OF PARTICIPANTS IN OUR CLINICAL TRIALS REMAIN OUR HIGHEST PRIORITY, AND WE ARE COMMITTED TO TRANSPARENCY
Reuters · 5d ago
PFIZER: DOES NOT ANTICIPATE ANY IMPACT TO SAFETY FOR PATIENTS TREATED WITH APPROVED MARSTACIMAB
Reuters · 5d ago
FLAGSHIP PIONEERING AND REPERTOIRE® IMMUNE MEDICINES ANNOUNCE AGREEMENT TO IDENTIFY T CELL-TARGETED IMMUNE MEDICINES FOR PROSTATE CANCER UNDER STRATEGIC PARTNERSHIP WITH PFIZER
Reuters · 6d ago
RPT-BUZZ-US stocks weekly: A tiny timid move
Reuters · 6d ago
BUZZ-US stocks weekly: A tiny timid move
Reuters · 12/19 21:36
CIPLA - AGREEMENT FOR COREX, DOLONEX, NEKSIUM AND DALACIN C BRANDS FOR 5 YEARS
Reuters · 12/19 06:01
Pfizer Inc. published an update to their financial calendar
Reuters · 12/18 15:00
UPDATE 3-AbbVie, several other pharma companies near MFN deal with Trump, sources say
Reuters · 12/17 20:51
PFIZER: SAFETY PROFILE FOR PADCEV PLUS PEMBROLIZUMAB WAS CONSISTENT WITH KNOWN PROFILE OF TREATMENT REGIMEN
Reuters · 12/17 11:45
Pfizer Inc. Publishes Transcript of Analyst and Investor Call Reviewing Full-Year 2026 Financial Guidance
Reuters · 12/17 03:26
LIVE MARKETS-US stocks end mixed after choppy session following data burst
Reuters · 12/16 21:20
BUZZ-U.S. STOCKS ON THE MOVE-Sunrun, PayPal, Caris
Reuters · 12/16 18:45
BUZZ-U.S. STOCKS ON THE MOVE-ADP, Bunge, Sunrun
Reuters · 12/16 15:46
PFIZER SHARES DOWN 0.7% AFTER CO FORECASTS 2026 PROFIT BELOW ESTIMATES
Reuters · 12/16 14:33
PFIZER EXEC SAYS CO DOES NOT ANTICIPATE DOING SHARE REPURCHASES IN THE NEAR TERM
Reuters · 12/16 13:13
PFIZER CEO SAYS ANTIVAX SENTIMENT AN ANOMALY, WILL CONTINUE INVESTING IN VACCINES
Reuters · 12/16 13:13
PFIZER CEO SAYS WELL POSITIONED FOR GROWTH IN 2029 AND 2030 - CONF CALL
Reuters · 12/16 13:13
PFIZER EXEC SAYS DEAL WITH U.S. GOVERNMENT COMPRESSING MARGINS IN 2026 DUE TO DISCOUNTS IN MEDICAID BUSINESS - CONF CALL
Reuters · 12/16 13:13
More
Webull provides a variety of real-time PFE-WI stock news. You can receive the latest news about PFIZER through multiple platforms. This information may help you make smarter investment decisions.
About PFE-WI
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.